CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)

Neuhaus, P.; Riess, Hanno; Post, Stefan; Gellert, Klaus; Ridwelski, K.; Schramm, H; Zuelke, Carl; Fahlke, J.; Langrehr, Jan M.; Burkart, Christoph; Oettle, Helmut

doi:10.1200/jco.2008.26.15_suppl.lba4504

Cited by 127 publications

(87 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1503 /cmaj .121368 / -/ DC1) and meta-analyses. Either gemcitabine or 5 -fluorouracil (5-FU) prolongs median survival by 3 months (95% CI 0.3-5.7), [28][29][30][31]49 …”

mentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and management of pancreatic cancer

Kanji

Gallinger

2013

CMAJ

View full text Add to dashboard Cite

“…1503 /cmaj .121368 / -/ DC1) and meta-analyses. Either gemcitabine or 5 -fluorouracil (5-FU) prolongs median survival by 3 months (95% CI 0.3-5.7), [28][29][30][31]49 …”

mentioning

confidence: 99%

“…[26][27][28][29][30][31][32][33][34][35][36][37][38][39] Twenty percent of cases are candidates for surgery and have CT evidence of no distant metastases, with the primary tumour free from the hepatic portal and superior…”

mentioning

confidence: 99%

Diagnosis and management of pancreatic cancer

Kanji

Gallinger

2013

CMAJ

View full text Add to dashboard Cite

“…Tani et al have reported that adjuvant chemotherapy was an independent factor affecting long-term survival in patients with locally advanced pancreatic cancer who had undergone surgery (10). Oettle et al have shown that adjuvant chemotherapy with GEM for pancreatic cancer patients was significantly effective for prolonging disease-free survival (7), and their subsequent study revealed that it was also capable of prolonging OAS (9). In their study, Ueno et al have shown that GEM prolonged diseasefree survival in patients who had undergone macroscopically curative resection of pancreatic cancer (8).…”

Section: Discussionmentioning

confidence: 95%

Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer

et al. 2011

View full text Add to dashboard Cite

Abstract. Adjuvant chemotherapy with gemcitabine is the standard treatment in Japan for patients who have undergone resection of pancreatic cancer. However, few reports have described suitable regimens for patients who present cancer relapse following adjuvant chemotherapy. In the present study, we retrospectively evaluated the efficacy and safety of S-1, an oral fluoropyrimidine derivative, as a second-line chemotherapy for patients who had suffered relapse of pancreatic cancer following adjuvant chemotherapy with gemcitabine. A total of 51 patients with pancreatic cancer suffered relapse after curative resection and subsequent adjuvant chemotherapy with gemcitabine at our institution. A group of 26 of these patients were administered S-1 orally twice daily after meals at a dose of 80 mg/m 2 for body surface areas for 14 consecutive days, followed by a 7-day rest (S-1 group). The remaining 25 patients received no additional anticancer drugs other than continuation of gemcitabine (GEM/BSC group). During a median follow-up period of 35 months, a significant difference was observed in overall survival (OAS) between the S-1 group and the control group (median OAS, 20.9 vs. 13.7 months; p=0.0157, log-rank test). Furthermore, there was a significant inter-group difference in survival after relapse (SAR) (median SAR, 11.4 vs. 6.20 months; p=0.0025,. No increase in grade 3/4 hematological and non-hematological toxicity was observed in the S-1 group. In conclusion, second-line chemotherapy using a combination of S-1 and adjuvant chemotherapy with gemcitabine may be an efficient and beneficial strategy for patients with relapsed pancreatic cancer.

show abstract

“…The available data from randomized phase III trials (ESPAC-1 and CONKO-001) indicate that adjuvant chemotherapy may substantially prolong DFS and cause a moderate increase of overall survival (18)(19)(20)(21). However, an optimal chemotherapy regimen remains to be defined.…”

Section: Discussionmentioning

confidence: 99%

“…However, an optimal chemotherapy regimen remains to be defined. Notably, in Italy as well as in Germany (4), gemcitabine chemotherapy [according to the CONKO-001 trial (20,21)] was the preferred schema, while aCT according to the ʻMayo regimenʼ [bolus 5-FU plus folinic acid, ESPAC-1 study (19)] was selected by few physicians. A reduction in toxicity was cited as the explanation, based on the ESPAC-3 trial, whereas gemcitabine was not superior to the Mayo regimen with respect to the primary end-point of overall survival, although the authors reported a 50% reduction of treatment-associated serious adverse events using gemcitabine (22).…”

Section: Discussionmentioning

confidence: 99%

Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey

Macchia

Sainato

Talamini³

et al. 2015

Oncology Reports

View full text Add to dashboard Cite

Abstract.No information is currently available regarding pancreatic cancer (PC) pattern of care in Italy. In the present study, a nationwide survey using a questionnaire was performed to enquire the local standards for PC diagnosis and radiotherapy treatment. Fifty-seven percent of 140 Italian centres completed questionnaire. The main causes of no radiotherapy indication were poor general condition (45%) and lack of guidelines (25%). Physicians (38%) employed neoadjuvant therapy in locally advanced PC patients, while in other centres (62%) adjuvant chemoradiation was administered. Adjuvant gemcitabine-based chemotherapy was selected as the treatment of choice by 59% of centres. Patients were treated mostly with doses of 50-54.9 Gy on the tumour (or bed) plus lymph nodes. A 3D-CRT technique was used in 81.2% of centres, while IMRT and IGRT were available in 61.2 and 48.7% of cases, respectively. Extensive variation exists with regard to patterns of care for PC in Italy. Nevertheless, cooperative studies emerging from this survey appeared beneficial.

show abstract

CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)

Cited by 127 publications

References 0 publications

Diagnosis and management of pancreatic cancer

Diagnosis and management of pancreatic cancer

Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer

Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey

Contact Info

Product

Resources

About